Skip to content

Considering the move from a BSC to an isolator?

A Cellectis manufacturing lead shares a practical playbook. Includes a downloadable guide to the details most teams learn the hard way.

Learn more

From skeptic to advocate: what Cellectis learned after two years with an isolator

Alaa Rashid wasn’t sold on isolators early on. As Director of US Manufacturing Operations at Cellectis, he watched his team spend eight to nine hours in the production suite in year one. Two years later, he can’t imagine going back to a BSC.

His story is not unique. As Advanced Therapy medicines continue to grow market share, and regulators increasingly demand documented justification for using a BSC rather than an isolator, many teams scaling up their manufacturing of cell therapies and personalized medicines find themselves in a bind.

The issue is not whether to transition manufacturing to an isolator: it’s well known that isolators outperform BSC in sterility assurance, with automated bio-decontamination achieving a 6-log reduction. It’s that transitioning to an isolator is far from straightforward. Questions around the logistical aspects of the transition loom large, and little, if any, practical guidance is available.

Cellectis, a company that develops advanced therapies for diseases that demand a lifetime of treatment, has already made the jump to an isolator. That’s why we asked Al to share practical tips on how his team managed the transition.

Critical areas to consider when making the transition

Hotspot image
  • The airlock

    Your biggest scheduling variable. Decontamination cycles are time-fixed and capacity-limited—you can’t rush them and you can’t overfill them. Learning to plan your workflow around the cycle is one of the most important operational skills your team will develop.

  • The built-in centrifuge

    Integrate, don’t transfer. Equipment built into the isolator eliminates the need to move materials in and out, reducing both contamination risk and time. Cellectis saved 1.5 hours per day with a single process change based on this principle.

  • The glove ports

    The detail most teams underestimate. Glove selection and fit significantly affect comfort and dexterity, and the wrong choice costs time. (See our guide below for what Cellectis learned after testing multiple options.)

  • The liquid transfer port

    Media, reagents, and other liquid inputs enter through this dedicated port without triggering a decontamination cycle. In cell culture, where some additions need to happen at a precise moment, that extra wait could cost you the batch.

“I wasn’t a big fan of isolators, to be honest.”

Alaa Rashid, Director of US Manufacturing Operations at Cellectis

The turning point

Al’s doubts, and the team’s initial challenges, stemmed mainly from the automation layer, which required a significant learning curve. Getting decontamination cycles, sensors, and reporting fully dialed in took roughly a year to a year and a half, he says, with SKAN providing hands-on support along the way.

Al’s conversion to advocate happened once he saw the results of the Aseptic Processing Simulations (APS) in the isolator.

Back when batches were processed in a BSC, he says, sterility failures were a recurring reality. That meant 20 days of production, all down the drain. “You already spent the money, you already made the batch, and then—gone, just like that,” he recalls.

After they made the switch, across 14 APS runs, only two resulted in failure—both traced to contaminated media from a supplier, not to the isolator itself. Once they changed that supplier, the failures stopped entirely.

Two years in: what changed

  • Sterility failure: eliminated

    Sterility failures were a recurring challenge in the BSC environment; since switching to isolators in 2021, zero failures across 28 production batches

  • Production time cut in half

    8–9 hrs/day in year one → 3.5–4 hrs/day now, once timing was built into batch records

  • 1.5 hours per day saved

    Moving the media exchange system inside the isolator saved 1.5 hours on every production day

  • 12 successful APS runs, 2 failures

    Both failures traced to contaminated supplier media, not the isolator

  • Less stringent background reqs

    ISO 8 background cleanroom (US) vs. ISO 6/7 for BSC

  • Improved working conditions

    Scrubs instead of full cleanroom gowning

  • Monthly EM, not weekly

    Isolator backgrounds generally require less frequent EM than BSC-based cleanrooms

  • Isolator know-how informs new processes

    New processes are now based on isolator workflows from the start

“Now I can’t imagine doing this process without the isolator.”

Alaa Rashid, Director of US Manufacturing Operations at Cellectis

The devil is in the details

Al’s biggest surprise? Loading time. “Cell therapy requires a lot of small items: pipettes, syringes, needles,” he said. “For 20 days, you use at least 40 to 50 of each.”

Loading everything through the airlock every day wasn’t an option—each decontamination cycle alone took 45 minutes, with limited capacity per load. His team had to plan ahead: deciding what to load into each chamber and qualifying each load in advance.

Then came surprise #2: raw materials from a refrigerator or freezer cannot be preloaded. “That’s when we found out it was going to take us at least three airlock loads every day to start our day—almost two hours just to load the materials we needed.” The team’s first two or three hours were spent just loading before they could actually start to work.

Over time, the team learned to anticipate what was needed and when, building load timing into their batch records. “We started planning it, and anticipating, okay, we’re going to need this item at this time, so let’s load it an hour before. And now it just flows very smoothly.”

“Now I always tell people you have to plan your loads correctly, because if not, your day is going to get longer and longer.”

An open material airlock within a stainless steel SKAN isolator, containing sterile laboratory supplies like vials, bottles, and bagged equipment on wire shelving.

Advice for teams considering the transition to an isolator

  • Don’t assume you can simply replicate a BSC process.

  • They can help understand different options (e.g., centrifuge bucket count, airlock size).

  • And document timing in batch records.

  • Cellectis ended up with the smallest available airlock due to room constraints.

  • Commit certain days to inside or outside work; back-and-forth wastes significant time.

  • Building in elements like centrifuges minimizes transfers outside of the isolator.

  • Small process tweaks (e.g., media change system inside the isolator rather than outside) can save 1.5 hours per day.

Note
While Cellectis’ process is built around allogeneic CAR-T manufacturing, these lessons apply broadly across ATMP processes. However, Al notes that not every cellular process is best suited to isolator-based production.

The bottom line

Most important, says Al, is to approach the transition to an isolator as you would any other significant change: with a holistic view, and with input and involvement from your teams.

“When we bought the isolator here, our process development colleagues were used to a BSC,” says Al. “So we brought some of them here to watch how we work.”

That cross-team observation paid off almost immediately: a single suggestion from the process development team led to a process change that saved 1.5 hours per day. Now they’re in the production suite an average of four hours, down from the original eight.

Two years in and 28 zero-failure batches later, Al’s verdict is unambiguous: “Guys, it’s worth it.”

Back to top